LTTS:NSEL&T Technology Services Ltd. Analysis
Data as of 2026-05-18 - not real-time
₹3,549.50
Latest Price
5/10Risk
Risk Level: Medium
Executive Summary
L&T Technology Services is trading around ₹3,550, just below its 20‑day SMA of ₹3,610 and comfortably above the identified support of ₹3,362, while the MACD shows a bearish crossover and volume is on a downtrend, suggesting limited upside in the near term. Valuation metrics reveal a trailing PE of ~30.7 against an industry average of ~38.6, yet the DCF‑derived fair value of roughly ₹1,475 implies the stock is significantly overvalued, with only a modest 3% upside to consensus target prices. Fundamentally, the company maintains healthy profitability with a gross margin of 41% and operating margin of 15%, and its cash pile of ₹30.8 bn dwarfs a modest debt of ₹5.8 bn, resulting in a low leverage profile. The dividend yield of 1.66% and a payout ratio under 50% support the claim of sustainability. Recent earnings reports note a slight revenue dip but an improving EBIT margin, and the firm announced its highest ever dividend, reinforcing shareholder returns. Strategic collaborations in digital engineering and sustainability, combined with exposure to North American and European markets, provide a solid growth platform despite the current valuation stretch. Overall, the stock appears to be in a neutral technical zone, with fundamental strengths offset by a pricing premium that limits near‑term upside.
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 6/10
Key Factors
- Bearish MACD histogram and decreasing volume
- Price trading below 20‑day SMA
- Support level still intact, limiting downside
Medium Term
1–3 yearsNeutral
Model confidence: 7/10
Key Factors
- Improving EBIT margins and strong cash generation
- Attractive dividend yield with sustainable payout
- Valuation still premium to DCF fair value
Long Term
> 3 yearsNeutral
Model confidence: 7/10
Key Factors
- Strategic positioning in high‑growth digital engineering segments
- Robust balance sheet and low leverage
- Overvaluation relative to intrinsic estimates may cap upside
Key Metrics & Analysis
Financial Health
Revenue Growth-4.20%
Profit Margin11.63%
P/E Ratio30.7
ROE19.54%
ROA9.87%
Debt/Equity8.91
P/B Ratio6.1
Op. Cash Flow₹14.6B
Free Cash Flow₹10.0B
Industry P/E38.6
Technical Analysis
TrendNeutral
RSI49.4
Support₹3,362.00
Resistance₹3,847.90
MA 20₹3,610.92
MA 50₹3,421.46
MA 200₹3,974.03
MACDBearish
VolumeDecreasing
Fear & Greed Index88.46
Valuation
Fair Value₹1,475.35
Target Price₹3,658.83
Upside/Downside3.08%
GradeOvervalued
TypeBlend
Dividend Yield1.66%
Risk Assessment
Beta0.25
Volatility35.21%
Sector RiskMedium
Reg. RiskMedium
Geo RiskMedium
Currency RiskLow
Liquidity RiskMedium
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.